Nonglucuronidated Ezetimibe Disrupts CD13- and CD64-Coassembly in Membrane Microdomains and Decreases Cellular Cholesterol Content in Human Monocytes/Macrophages.

Authors:
Horst Robenek
Horst Robenek
Leibniz Institute for Arteriosclerosis Research
Germany
Alfred Boettcher
Alfred Boettcher
University of Regensburg
Germany
Zsuzsanna Wolf
Zsuzsanna Wolf
Institute for Clinical Chemistry and Laboratory Medicine
Germany
Gerhard Liebisch
Gerhard Liebisch
University of Regensburg
Germany
Gerd Schmitz
Gerd Schmitz
University of Regensburg
Germany

Cytometry A 2019 Apr 17. Epub 2019 Apr 17.

Institute for Clinical Chemistry and Laboratory Medicine, University Hospital of Regensburg, 93053 Regensburg, Germany.

Ezetimibe (EZE) and glucuronidated EZE (EZE-Glu) differentially target Niemann-Pick C1-like 1 (NPC1L1) and CD13 (aminopeptidase-N) to inhibit intestinal cholesterol absorption and cholesterol processing in other cells, although the precise molecular mechanisms are not fully elucidated. Cellular effects of EZE, EZE-Glu, and the low-absorbable EZE-analogue S6130 were investigated on human monocyte-derived macrophages upon loading with atherogenic lipoproteins. EZE and S6130, but not EZE-Glu disturbed the colocalization of CD13 and its coreceptor CD64 (Fcγ receptor I) in membrane microdomains, and decreased the presence of both receptors in detergent-resistant membrane fractions. Biotinylated cholesterol absorption inhibitor C-5 (i.e., derivative of EZE) was rapidly internalized to perinuclear tubular structures of cells, resembling endoplasmic reticulum (ER), but CD13 was detected on extracellular sites of the plasma membrane and endolysosomal vesicles. Administration of EZE, but not of EZE-Glu or S6130, was associated with decreased cellular cholesteryl ester content, indicating the sterol-O acyltransferase 1 (SOAT1)-inhibition by EZE. Furthermore, EZE decreased the expression of molecules involved in cholesterol uptake and synthesis, in parallel with increased apolipoprotein A-I-mediated cholesterol efflux and upregulation of efflux-effectors. However, NPC1L1 the other claimed molecular target of EZE, was not detected in macrophages, thereby excluding this protein as target for EZE in macrophages. Thus, EZE is very likely a CD13-linked microdomain-disruptor and SOAT1-inhibitor in macrophages leading to in vitro anti-atherosclerotic effects through a decrease of net cellular cholesterol content. © 2019 International Society for Advancement of Cytometry.

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/cyto.a.23772
Publisher Site
http://dx.doi.org/10.1002/cyto.a.23772DOI Listing

Still can't find the full text of the article?

We can help you send a request to the authors directly.
April 2019
6 Reads

Publication Analysis

Top Keywords

eze eze-glu
12
eze
11
cellular cholesterol
8
cholesterol content
8
membrane microdomains
8
target eze
8
cholesterol absorption
8
cholesterol
7
perinuclear tubular
4
detected macrophages
4
internalized perinuclear
4
biotinylated cholesterol
4
detergent-resistant membrane
4
macrophages excluding
4
membrane fractions
4
fractions biotinylated
4
npc1l1 claimed
4
absorption inhibitor
4
derivative eze
4
molecular target
4

References

(Supplied by CrossRef)

Similar Publications